Interactions Between P-Glycoprotein and Drugs Used in the Supportive Care of Acute Myeloid Leukemia Patients

References

• Bradshaw D. M., Arcesi R. I. Clinical Relevance of transmembrane drug efflux as mechanism of multidrug resistance. Journal of Clinical Oncology 1998; 16: 3674–3690
   PubMed Web of Science ®Google Scholar
• Germann U. A. P-glycoprotein-a mediator of multidrug resistance in tumour cells. European Journal of Cancer 1996; 32A: 927–944
   PubMed Web of Science ®Google Scholar
• McKenna S. L., Padua R. A. Multidrug resistance in leukemia. British Journal of Haematology 1996; 96: 659–674
   Web of Science ®Google Scholar
• Hyde S. C., Emsley P., Hartshorn M. J., Mimmack M. M., Gileadi U., Pearce S. R., Gallagher M. P., Gill D. R., Hubbard R. E., Higgins C. F. Structure model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance, and bacterial transport. Nature 1990; 346: 362–365
   PubMed Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsurao T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphocytic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Gruber A., Vitolas S., Norgren S., Arestrom L., Peterson C., Bjorkholm M., Reizenstein P., Luthman H. Quantitative determination of mdrl gene expression in leukaemic cells from patients with acute leukaemia. British Journal of Cancer 1992; 66: 266–272
   PubMed Web of Science ®Google Scholar
• Legrand O., Simonin G., Beauchamp-Nicoud A., Zittoun R., Marie J. P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and in vivo resistance in adult acute myeloid leukemia. Blood 1999; 94: 1046–1056
   PubMed Web of Science ®Google Scholar
• Leith C. P., Kopecky K. J., Godwin J., McConnell T., Slovak M. L., Chen I. M., Head D. R., Appelbaum F. R., Willman C. L. Acute myeloid leukemia in the elderly: Assassment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329
   PubMed Web of Science ®Google Scholar
• Leith C. P., Kopecky K. J., Chen I. M., Eijdems L., Slovak M. L., McConnell T. S., Head D. R., Weick J., Grever M. R., Appelbaum F. R., William C. L. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein. MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086–1099
   PubMed Web of Science ®Google Scholar
• Nooter K. K., Sonneveld P., Oostrum R., Herweijer H., Hagenbeek T., Valerio D. Overexpression of the mdrl gene in blast cells from patients with acute myeloytic leukemia is associated with decresed anthracycline accumulation that can be restored by cyclosporin A. International Journal of Cancer 1990; 45: 263–268
   PubMed Web of Science ®Google Scholar
• Zhou D. C., Marie J. P., Suberville A. M., Zittoun R. Relevance of mdrl gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879–885
   PubMed Web of Science ®Google Scholar
• Broxterman H. J., Sonneveld P., Feller N., Ossenkoppele G. J., Währer D. C., Eekman C. A., Schoester M., Lankelma J., Pinedo H. M., Löwenberg B., Schuurhuis G. J. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity. Blood 1996; 87: 4809–4816
   PubMed Web of Science ®Google Scholar
• Ludescher C., Thaler J., Drach D., Spitaler M., Gattringer C., Huber H., Hofmann J. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. British Journal of Haematology 1992; 82: 161–168
   PubMed Web of Science ®Google Scholar
• Jiang X. R., Kelsey S. M., Wu Y. L., Newland A. C. Circumvention of P-glycoprotein-mediated drug resistance in human leukemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. British Journal of Haematology 1995; 90: 375–383
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Research 1981; 41: 1967–1972
   PubMed Web of Science ®Google Scholar
• Twentyman P. R. Cyclosporins as drug resistance modifiers. Biochemical Pharmacology 1992; 43: 109–117
   PubMed Web of Science ®Google Scholar
• Ford J. M., Hait W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacological Reviews 1990; 42: 155–199
   PubMed Web of Science ®Google Scholar
• Ford J. M. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. European Journal of Cancer 1996; 32A: 991–1001
   PubMed Web of Science ®Google Scholar
• Nooter K., Oostrum R., Jonker R., van Dekken H., Stokdijk W., Van den Engh G. Effect of cyclosporine A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry. Cancer Chemotherapy and Pharmacology 1989; 23: 296–300
   PubMed Web of Science ®Google Scholar
• Ford J. M. Modulators of multidrug resistance. Preclinical studies. Hematology/Oncology Clinics of North America 1995; 9: 337–361
   PubMed Web of Science ®Google Scholar
• Horton J. K., Thimmaiah K. N., Houghton J. A., Horowitz M. E., Houghton P. J. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenofrafts. Biochemical Pharmacology 1989; 38: 1727–1736
   PubMed Web of Science ®Google Scholar
• Slater L. M., Sweet P., Stupecky M., Wetzel M. W., Gupta S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. British Journal of Cancer 1986; 54: 235–238
   PubMed Web of Science ®Google Scholar
• Childs S., Ling V. The MDR superfamily of genes and its biological implications. Important Advances in Oncology, V. DeVita, S. Hellman, S. A. Rosenberg. JB Lippincott Company, Philadelphia 1994; 21–36
   Google Scholar
• Chaudhary P. M., Roninson I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stemcells. Cell 1991; 66: 85–94
   PubMed Web of Science ®Google Scholar
• Gosland M. P., Lum B. L., Sikic I. Reversal by cefoperazone of resistance to etoposide, doxorubicin and vinblastine in multidrug resistant sarcoma cells. Cancer Research 1989; 49: 6901–6905
   PubMed Web of Science ®Google Scholar
• Hofsli E., Nissen-Meyer J. Effect of erythromycin and tumor necrosis factor on the drug resistance of multidrug-resistant cells: Reversal of drug resistance by erythromycin. International Journal of Cancer 1989; 43: 520–525
   PubMed Web of Science ®Google Scholar
• Kavallaris M., Madafiglio J., Norris M. D., Haber M. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells. Biochemical and Biophysical Research Communications 1993; 190: 79–85
   PubMed Web of Science ®Google Scholar
• Jönsson K., Dahlberg N., Tidefelt U., Paul C., Andersson G. Characterisation of an anthracycline resistant human promyelocytic leukemia (HL-60) cell line with an elevated MDR-1 gene expression. Biochemical Pharmacology 1995; 49: 755–762
   PubMed Web of Science ®Google Scholar
• Campana D., Manabe A., Evans W. E. Stroma-supported immunocytometric assay (SLA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs. Leukemia 1993; 3: 482–488
   Google Scholar
• Coune A. Amphotericin B as a potentiation agent to cytotoxic chemotherapy. European Journal of Cancer and Clinical Oncology 1988; 24: 117–121
   PubMedGoogle Scholar
• Lautier D., Canitrot Y., Deeley R. G., Cole S. P. Multidrug resistance mediated by the multidrug resistance (MRP) gene. Biochemical Pharmacology 1996; 52: 967–977
   PubMed Web of Science ®Google Scholar
• Twentyman P. R., Rhodes T., Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. European Journal of Cancer 1994; 30A: 1360–1369
   PubMed Web of Science ®Google Scholar
• List A. F. Non-P-glycoprotein drug export mechanisms of multidrug resistance. Seminars in Hematology 1997; 34: 20–24
   PubMed Web of Science ®Google Scholar
• Scheper R. J., Broxterman H. J., Scheffer G. L., Kaajik P., Dalton W. S., van Heijningen T. H., van Kalken C. K., Slovak M. L., de Vries E. G., van der Valk P., Meijer C. J., Pinedo H. M. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Research 1993; 53: 1475–1479
   PubMed Web of Science ®Google Scholar
• Poulain L., Sichel F., Crouet H., Bureau F., Gauduchon P., Gignoux M., Le Talaër J. Y. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells. Cancer Chemotherapy and Pharmacology 1997; 40: 385–390
   PubMed Web of Science ®Google Scholar